Abstract
The third member of transforming acidic coiled-coil protein (TACC) family, TACC3, has been shown to be an important player in the regulation of centrosome/microtubule dynamics during mitosis and found to be deregulated in a variety of human malignancies. Our previous studies have suggested that TACC3 may be involved in cervical cancer progression and chemoresistance, and its overexpression can induce epithelial-mesenchymal transition (EMT) by activating the phosphatidylinositol 3-kinase (PI3K)/Akt and extracellular signal-regulated protein kinases (ERKs) signal transduction pathways. However, the upstream mechanisms of TACC3-mediated EMT and its functional/clinical importance in human cervical cancer remain elusive. Epidermal growth factor (EGF) has been shown to be a potent inducer of EMT in cervical cancer and associated with tumor invasion and metastasis. In this study, we found that TACC3 is overexpressed in cervical cancer and can be induced upon EGF stimulation. The induction of TACC3 by EGF is dependent on the tyrosine kinase activity of the EGF receptor (EGFR). Intriguingly, depletion of TACC3 abolishes EGF-mediated EMT, suggesting that TACC3 is required for EGF/EGFR-driven EMT process. Moreover, Snail, a key player in EGF-mediated EMT, is found to be correlated with the expression of TACC3 in cervical cancer. Collectively, our study highlights a novel function for TACC3 in EGF-mediated EMT process and suggests that targeting of TACC3 may be an attractive strategy to treat cervical cancers driven by EGF/EGFR signaling pathways.

Introduction
Epithelial-mesenchymal transition (EMT) is a highly conserved biological process that results in a conversion of polarized epithelial cells to mesenchymal cell types characterized by the loss of E-cadherin-mediated cell-cell contacts as well as the acquisition of increased migratory and invasive potentials [1–9]. Transcriptional factors Snail, Slug, Twist and Zeb1 have been identified as negative regulators of E-cadherin and are considered to be potent oncogenic inducers of EMT [10–14].

Despite the great success of early screening programs, cervical cancer is still the leading cause of gynecological death among women worldwide [15,16]. Human papillomaviruses (HPVs) are thought to be the main cause of cervical cancer; however, studies have shown that the virus alone is not enough to develop cancer [15,17,18]. Epidermal growth factor (EGF) has been shown to be one of the most potent inducers of EMT in cervical cancer and associated with cervical stromal invasion and nodal metastasis [15,19]. Chronic EGF treatment induces EMT via up-regulation of EMT-inducing transcription factor Snail in cervical cancer cells, and EGF-mediated EMT is correlated with EGF receptor (EGFR) overexpression and clinical progression of cervical cancer [15,20]. The expression of EGF has been found to be overexpressed in cervical cancer [21].

The transforming acidic coiled-coil protein (TACC) family is characterized by a conserved C-terminal “TACC domain”, essential for the interaction with tubulin and microtubules [22–24] and has been known to play a key role in the regulation of centrosome and microtubule dynamics [22,25–29]. There are three TACC proteins identified in human: TACC1, TACC2 and TACC3 [24,30–32]. TACC3 is involved in the assembly and organization of microtubules and chromosome alignment during mitosis, the maintenance of nuclear envelope structure and the regulation of cell growth/differentiation and gene transcription [24,26,27,29,33–38]. Depletion of TACC3 causes growth retardation and embryonic lethality in mice due to increased apoptosis [39].

Although the role of TACC3 in human cancer is not clear, mounting evidence suggests that deregulation of TACC3 may be directly or indirectly linked to certain types of human cancer [24]. Genetic variations on chromosome 4p16.3, the region encoding TACC3, are found in various human cancers [9,24,40–48]. The fibroblast growth factor receptor 3 gene (FGFR3) and TACC3 are closely localized on chromosome 4p16.3 [9,32]. Recently, a TACC3-FGFR3 fusion protein was reported in a subset of glialoblastoma multiforme (GBM) [49] and bladder tumors and cell lines [50]. This fusion protein induces mitotic defects and aneuploidy and activates mitogen-activated protein kinase (MAPK) signaling pathway [49,50]. So far, a somatic mutation (E660K) and two constitutional mutations (S93L and G514E) of TACC3 have been identified in GBM and ovarian cancer, respectively [40,51,52]. Studies have shown that up-regulation of TACC3 is found in glioblastoma, non-small cell lung cancer (NSCLC) and multiple myeloma [40,53,54] and may contribute to
lymphomagenesis [55,56]. Gene expression profiling analysis has revealed that TACC3 is up-regulated during the transition of ductal carcinoma in situ to invasive carcinoma of the breast and in ovarian cancer [57–59]. We have previously proposed that TACC3 may be directly or indirectly associated with tumor progression and drug resistance of cervical cancer, based upon data acquired from microarray analysis to identify genes regulated by TACC3 [24,60]. Moreover, our recent study has shown that ectopic expression of TACC3 enhances proliferation, migratory/invasive ability and transformation capacity of HeLa cervical cancer cells and displays a more mesenchymal phenotype, accompanied by down-regulation of epithelial marker E-cadherin and up-regulation of mesenchymal markers N-cadherin and Vimentin as well as EMT inducers Snail and Slug [9]. On the other hand, depletion of TACC3 is capable of reversing/suppressing EMT [9]. Although our findings indicate that TACC3 may play an important role in EMT, the upstream signaling events responsible for TACC3-mediated EMT remain to be determined.

Herein, we demonstrate that TACC3 is overexpressed in cervical cancer. TACC3 can be induced by EGF, and EGF-mediated TACC3 induction is dependent on EGFR activation. Importantly, in the absence of TACC3, EGF is not able to induce EMT, suggesting that TACC3 is necessary for EGF-mediated EMT in cervical cancer. Moreover, we find a correlation between TACC3 and EGF inducer Snail in cervical cancer. Our findings, therefore, identify a novel mechanism that mediates EGF/EGFR-induced EMT and a potential therapeutic target for cervical cancer.

Materials and Methods

Tissue Microarrays and Immunohistochemistry

Cervical cancer tissue microarrays (CR005, CR1003 and CR1501) were purchased from US Biomax (Rockville, MD). Tissue microarray patient information is shown in Table 1. Tissue microarray slides were deparaffinized, rehydrated and heat-treated for antigen retrieval prior to antibody staining [61]. The slides were incubated with an anti-TACC3 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h at room temperature, followed by incubation with secondary biotinylated antibody and the Avidin-Biotin complex (ABC) in accordance with the Vectastain ABC kit protocol (Vector Laboratories, Burlingame, CA). After developing color with diaminobenzidine (DAB), the slides were independently assessed by authors. The intensity of staining was recorded as follows: 0 for negative expression; 1+ for weakly positive expression; 2+ for medium positive expression; and 3+ for highly positive expression. Photomicrograph (magnification ×100) was taken by DP12 microscope (Olympus, Tokyo, Japan) equipped with DP71 digital imaging system (Olympus).

Cell Culture, Antibodies and Reagents

The human cervical cancer (HeLa, CaSki, SiHa and C33A) and HPV-immortalized ectocervical epithelium (Ect1/E6E7) cell lines were purchased from the American Type Culture Collection (ATCC) (Manassas, VA). HeLa cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) (HyClone, Logan, UT) supplemented with 10% fetal bovine serum (FBS) (Gemini Bio-Products, Woodland, CA) and 1% penicillin/streptomycin solution (Thermo Fisher Scientific, Waltham, MA). CaSki cells were maintained in RPMI-1640 medium (HyClone) containing 10% FBS and 1% penicillin/streptomycin solution. SiHa and C33A cells were grown in MEM (HyClone) supplemented with 10% FBS and 1% penicillin/streptomycin solution. Ect1/E6E7 cells were grown in Keratinocyte-Serum Free medium (Ker-SFM; Gibco/BRL Life Technologies, Gaithersburg, MD) with 0.1 mg/ml human recombinant EGF, 0.05 mg/ml bovine pituitary extract and additional calcium chloride 44.1 mg/L (final concentration 0.4 mM). Cells were incubated at 37°C in a humidified incubator with 5% CO2. Anti-TACC3 antibody was purchased from Santa Cruz Biotechnology. Antibodies against E-cadherin, N-cadherin, Vimentin, Snail, Slug and EGFR were purchased from Cell Signaling Technology (Beverly, MA). Anti-b-actin antibody and EGF were purchased from Sigma (St. Louis, MO). The EGFR kinase inhibitor AG1478 was purchased from Selleckchem (Houston, TX).

**shRNA and Transfection**

Cells were transfected with a TACC3-specific or a control shRNA (Santa Cruz Biotechnology) by using FuGene 6 (Roche Molecular Biochemicals, Indianapolis, IN) according to the manufacturer’s instructions.

**Western Blot Analysis**

Human normal cervix tissue lysates were purchased from Imgenex (San Diego, CA). Cell extracts were prepared in a lysis buffer consisting of 50 mM Tris-Cl (pH 7.4), 1% nonyl phenoxypolyethoxyethanol (NP-40), 0.25% sodium deoxycholate, 150 mM sodium chloride (NaCl), 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium fluoride (NaF) and Complete protease inhibitor cocktails (Roche Molecular Biochemicals). Cell lysates were cleared by centrifugation at 13,000 rpm for 10 min, and the supernatants were subjected to western blot analysis. Equal amounts of protein were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membrane. After blocking with Tris-buffered saline (TBS)/0.1% Tween 20 (TBS-T) supplemented with 5% nonfat dry milk for 1 h, membranes were incubated with primary antibodies diluted in blocking buffer for 2 h at room temperature or overnight at 4°C, followed by incubation with horseradish

---

**Table 1. Cervical cancer tissue microarray information.**

| Variable | n | Variable | n | Variable | n |
|----------|---|----------|---|----------|---|
| Age (years) | | Age (years) | | Age (years) | |
| <50 | 56 | <50 | 56 | <50 | 84 |
| ≥50 | 24 | ≥50 | 44 | ≥50 | 66 |
| FIGO stage | | FIGO stage | | FIGO stage | |
| Ia | 7 | Ia | 48 | I | 68 |
| Ib | 15 | Ib | 10 | Ib | 40 |
| Ila | 3 | II | 10 | Ic | 2 |
| Iib | 17 | III | 2 | II | 14 |
| IIIa | 4 | IIBb | 10 | IIIa | 6 |
| IIIb | 24 | IIBb | 6 |

---

**Western Blot Analysis**

Human normal cervix tissue lysates were purchased from Imgenex (San Diego, CA). Cell extracts were prepared in a lysis buffer consisting of 50 mM Tris-Cl (pH 7.4), 1% nonyl phenoxypolyethoxyethanol (NP-40), 0.25% sodium deoxycholate, 150 mM sodium chloride (NaCl), 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM sodium fluoride (NaF) and Complete protease inhibitor cocktails (Roche Molecular Biochemicals). Cell lysates were cleared by centrifugation at 13,000 rpm for 10 min, and the supernatants were subjected to western blot analysis. Equal amounts of protein were separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membrane. After blocking with Tris-buffered saline (TBS)/0.1% Tween 20 (TBS-T) supplemented with 5% nonfat dry milk for 1 h, membranes were incubated with primary antibodies diluted in blocking buffer for 2 h at room temperature or overnight at 4°C, followed by incubation with horseradish...
Figure 1. TACC3 is overexpressed in cervical cancer cell lines and tissues. (A) The expression of TACC3 in Ect1/E6E7 (HPV-immortalized ectocervical epithelia), CaSki (HPV-16), C33A (HPV-negative), SiHa (HPV-16) and HeLa (HPV-18) cell lines was determined by western blot analysis. The expression levels were compared to three normal cervix tissues. β-actin was used as a loading control. The intensity of bands was quantified using imageJ software and normalized to β-actin. Data shown are means ± SD of at least three independent experiments. (B) Representative immunohistochemical staining on cervical cancer tissue microarray. Quantitative analysis of cervical cancer tissue microarrays showed that the expression of TACC3 is higher in cervical cancer than in normal cervix, but its expression does not correlate with tumor stage (C) or grade (D). Data shown are means ± SD of at least three independent experiments. *, p<0.05; **, p<0.001.

doi:10.1371/journal.pone.0070353.g001
Figure 2. EGF stimulation induces the expression of TACC3. (A) Cervical cancer cells treated with EGF showed a morphological change associated with EMT. (B and C) Both protein (B) and mRNA (C) levels of TACC3 were up-regulated upon EGF stimulation, along with down-regulation of E-cadherin and up-regulation of Vimentin, Snail and Slug. β-actin was used as loading control. The intensity of bands was quantified using imageJ.
software and normalized to β-actin. The mRNA level of TACC3 was represented relative to β-actin transcripts. Data shown are means ± SD of at least three independent experiments. (D and E) HeLa and SiHa cells treated with or without EGF were subjected to transwell migration (D) and Matrigel invasion assays (E) (see Materials and Methods). Cells were incubated with or without 50 ng/ml of EGF for 24 h. Data shown are means ± SD of at least three independent experiments. *, p<0.05; **, p<0.01; ***, p<0.005; ****, p<0.001.

doi:10.1371/journal.pone.0070353.g002

**Figure 3.** TACC3 is induced upon EGF stimulation in EGFR-expressing cells. C33A cells treated with EGF did not show significant changes in cell morphology (A), expression of TACC3 and EMT markers (B), or motility (C). Cells were incubated with or without 50 ng/ml of EGF for 24 h and then subjected to western blot and transwell migration assays. The intensity of bands was quantified using imageJ software and normalized to β-actin. Data shown are means ± SD of at least three independent experiments. (D) The expression of EGFR in Ect1/E6E7, CaSki, C33A, SiHa and HeLa cell lines was determined by western blot analysis. β-actin was used as a loading control. The intensity of bands was quantified using imageJ software and normalized to β-actin. Data shown are means ± SD of at least three independent experiments.

doi:10.1371/journal.pone.0070353.g003
Figure 4. EGF-mediated TACC3 induction is dependent on EGFR activation. The inhibition of tyrosine kinase activity of EGFR abolished a morphological change associated with EMT (A) and EGF-mediated TACC3 induction (B). Cells were treated with EGF or EGF+AG1478 for 24 h and then subjected to western blot analysis. β-actin was used as a loading control. The intensity of bands was quantified using imageJ software and normalized to β-actin. Data shown are means ± SD of at least three independent experiments. *, p<0.001.

doi:10.1371/journal.pone.0070353.g004
Figure 5. TACC3 is required for EGF-mediated EMT. In the absence of TACC3, EGF was not able to regulate EMT markers (A), alter cell morphology (B), or enhance cell migration and invasion capabilities (C and D). Cells were transiently transfected with shRNAs against control (scrambled, shCon) or TACC3 (shTACC3) and treated with or without EGF for 24 h. Cells were then subjected to western blot, transwell migration and invasion assays.
peroxidase (HRP)-conjugated secondary antibodies (Bio-Rad, Hercules, CA) for 1 h at room temperature. Finally, antigen-antibody complexes were detected by the enhanced chemiluminescence (GE Healthcare, Buckinghamshire, UK). Bands were quantified using ImageJ software [http://rsb.info.nih.gov/ij/, NIH, Bethesda, MD] and normalized to β-actin.

Quantitative Real Time-polymerase Chain Reaction (qRT-PCR)

Total RNAs from cells were extracted using the RNeasy® mini kit (Qiagen Sciences, Germantown, MD) and then subjected to cDNA synthesis using the RevertAid™ First Strand cDNA Synthesis Kit (Fermentas Life Sciences Europe, Bremen, Germany). Expression of genes was analysed using an iQ™ SYBR® Green supermix (Bio-Rad) and an iCycler iQ5 real-time PCR detection system (Bio-Rad). The following cycling conditions were used: 95°C for 5 min and 30 sec, followed by 40 cycles of 15 sec at 95°C and 1 min at 60°C. Data was analyzed with a normalized gene expression method (ΔΔ Ct) [62] using the iQ5 Optical System Software (Bio-Rad), and the β-actin was used as a reference for normalization. The sequences of the primer pairs were as follows: TACC3 5’-gaactggggaagatcatgga-3' and 5’-ctcttcgttcttgcggtagc-3' [63]; β-actin 5actinINK \( \text{Ulisse, 2007 } \) 39 and 5’-ctcttcgttcttgcggtagc-3’ [64]. All the measurements were performed in triplicate.

Figure 6. A correlation between TACC3 and Snail expression in cervical cancer tissue microarray. (A) Representative immunohistochemical staining of TACC3 and Snail on cervical cancer tissue microarray. Quantitative analysis of cervical cancer tissue microarrays showed that (B) the expression of Snail is higher in cervical cancer than in normal cervix. Data shown are means ± SD of at least three independent experiments. *, p<0.001. (C) Snail expression correlates with TACC3 expression (r = 0.80383, p < 0.0001). doi:10.1371/journal.pone.0070353.g006
Transwell Migration Assay

Uncoated cell culture inserts (8-μm pores, 24-well) (Greiner Bio-One, Monroe, NC) were seeded with 1 × 10^5 cells in 200 μl of serum-free media. The lower chambers were filled with 750 μl of complete media containing 10% FBS. After 16 h of incubation, cells on the upper surface of the filter were wiped off, and cells that had migrated to the lower surface of the filter were fixed with 4% paraformaldehyde or ice cold methanol for 5 min, stained with 0.05% crystal violet for 20 min and quantified spectrophotometrically at 490 nm.

Invasion Assay

Invasion assays were performed using the QCM ECMatrix cell invasion assay kits (Millipore, Temecula, CA) according to the manufacturer’s instructions.

Statistical Analysis

Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad, San Diego, CA). Significance was determined by t-test and one-way Analysis of Variance (ANOVA), followed by the Tukey multiple comparison test. Pearson’s correlation coefficient was used to measure the correlation between two variables. A p-value of less than 0.05 was considered as statistical significance.

Results

TACC3 is Overexpressed in Cervical Cancer

To investigate the clinical importance of TACC3 in human cervical cancer, we first examined the expression of TACC3 mRNA in cervical cancer using the publicly available Oncomine database (www.oncomine.org, Compendia Bioscience, Inc., Ann Arbor, MI) [63] and determined that TACC3 is highly expressed in cervical cancer [66,67]. Overexpression of TACC3 in cervical cancer was further confirmed in several cervical cell lines, including Ect1/E6E7 (HPV-16 E6/E7 transformed ectocervical epithelium), CaSki (HPV-16), C33A (HPV-negative), HeLa (HPV-18) and SiHa (HPV-16) compared with three normal human cervix tissues. As shown in Figure 1A, the expression of TACC3 in these cell lines was higher than that of normal cervix tissues. Interestingly, there was no significant difference in the expression of TACC3 between HPV-negative C33A and other cells carrying HPV oncogenes (Ect1/E6E7, CaSki, HeLa and SiHa), suggesting that HPV infection may not be responsible for the overexpression of TACC3. We also immunohistochemically analyzed the expression of TACC3 using cervical cancer tissue microarrays. TACC3 was almost undetectable in normal cervix, whereas its strong expression was observed in cervical cancer tissues (Figure 1B). However, there was no significant association of TACC3 expression with clinical stage or grade of the disease (Figure 1C, 1D and S1). Based upon our findings that the expression of TACC3 is elevated in cervical cancer compared to normal cervix but not significantly associated with disease progression, we suggest that increased expression of TACC3 may occur in the early stages of tumor development as well as be essential in maintaining cervical tumorigenesis.

EGF Stimulation Induces Endogenous TACC3 Expression in EGFR-expressing Cells

Our previous study indicated that overexpression of TACC3 induces EMT, accompanied by down-regulation of E-cadherin and up-regulation of Snail and Slug, whereas depletion of TACC3 reverses EMT [9]. In addition, the activation of Akt and ERK signaling pathways is essential for TACC3-mediated EMT [9]. Here, we sought to determine how TACC3 participates in EMT. Diverse growth factors, such as EGF, transforming growth factor β (TGF-β) and insulin-like growth factor 1 (IGF-1) have been shown to induce EMT and are significantly associated with the invasiveness, metastasis and recurrence of cervical cancer [15,68–70]. EGF has been shown to induce EMT via up-regulation of Snail in cervical cancer cells [15] and activate Akt and ERK signaling pathways [71,72]. Based upon these studies, we hypothesized that TACC3 may be involved in EGF-mediated EMT.

To test our hypothesis, we treated HeLa, CaSki and SiHa cells with 50 ng/ml of EGF for 24 h and then examined the morphological changes of cells and the expression of the EMT markers. As shown in Figure 2A, cells treated with EGF displayed morphological and phenotypical features of EMT. Intriguingly, both protein (Figure 2B) and mRNA (Figure 2C) levels of TACC3 were significantly increased upon EGF stimulation, accompanied by down-regulation of epithelial marker E-cadherin and up-regulation of mesenchymal marker Vimentin as well as EMT inducers Snail and Slug in HeLa, CaSki and SiHa cells (Figure 2B). Time course experiments were also performed to verify the induction of TACC3 upon EGF stimulation. EGF induced a sustained expression of TACC3 in CaSki and SiHa cells up to 48 h, while a temporary increase in TACC3 expression was found in HeLa cells (Figure S2). We also found that EGF promoted migratory and invasive capabilities of HeLa and SiHa cells (Figure 2D and 2E), consistent with other studies [15,73]. We did not see any significant changes in cell morphology (Figure 2A), the expression of TACC3 and other EMT markers (Figure 3B), or motility (Figure 3C) in EGF-treated C33A cells. This is most likely because C33A expresses very low or undetectable levels of EGFR (Figure 3D). These results suggest that EGFR is required for EGF-mediated induction of TACC3 and subsequent EMT.

Activation of EGFR is Required for EGF-mediated Induction of TACC3

As our data indicates that EGF treatment can increase the expression of TACC3 in EGFR-expressing cells, we questioned whether EGF-mediated induction of TACC3 is dependent on the tyrosine kinase activity of EGFR. AG1478 is a tyrosine kinase inhibitor of EGFR, which blocks EGFR-mediated signaling events [74,75]. Treatment with 5 μM of AG1478 abolished EGF-induced morphological changes (Figure 4A) and TACC3 induction (Figure 4B), and as a consequence, EGF-mediated EMT was inhibited (Figure 4B). This data suggests that activation of EGFR is required for EGF-mediated TACC3 induction.

TACC3 is Required for EGF-mediated EMT Process

Since both TACC3 and EGF can promote EMT through the activation of PI3K/Akt and ERK signaling pathways [9,71,72], and TACC3 can be up-regulated upon EGF stimulation (Figure 2B, 2C and S2), we questioned whether TACC3 plays an important role in EGF-mediated EMT. To address this question, we depleted TACC3 using a lentiviral vector delivering shRNA specific to TACC3 in HeLa and SiHa cells and treated with or without EGF. As we previously reported [9], depletion of TACC3 led to the up-regulation of E-cadherin and down-regulation of Vimentin, Snail and Slug in HeLa and SiHa cells compared to control cells (Figure 5A). Intriguingly, EGF treatment on TACC3-depleted cells was not able to revert the expression of EMT markers (Figure 5A), cell morphology (Figure 5B), cell migration (Figure 5C) or invasion capacity (Figure 5D). These findings suggest that TACC3 may play a key role in EGF-mediated EMT.
A Positive Correlation Exists between TACC3 and Snail Expression in Cervical Cancer

Snail has been known to be induced by EGF, thus triggering EGF-mediated EMT [15,76]. We found that TACC3 was also induced upon EGF stimulation (Figure 2B and 2C) and positively regulates the expression of Snail [9]. Therefore, we questioned whether there is any correlation between TACC3 and Snail expression in cervical cancer. Importantly, we found that the expression of Snail was elevated in cervical cancer (Figure 6A and 6B) and correlated with TACC3 expression (Figure 6C). However, TACC3 expression did not correlate with the expression of Slug, another member of the Snail family (data not shown).

Discussion

It has been suspected that deregulation (both up- and down-regulation) of TACC3 may be associated with the development of various types of human cancer [24,77,78]. So far, whether TACC3 acts as a tumor suppressor or an oncogene has not been clearly defined due to the discrepancies among studies [24,79]. Alternatively, TACC3 may have different functions depending on the type of cell or organ. In this study, we aimed to investigate the functional significance of TACC3 in cervical cancer. Our cervical cancer tissue microarray analysis revealed that the expression of TACC3 protein is up-regulated in cervical squamous cell carcinoma, the most common type of cervical cancer (approximately 80–90%) [80]. This is consistent with data obtained from Oncomine [67] and suggests its potential role as an oncogene in cervical cancer. Our study also suggests that the expression of TACC3 may not be regulated by HPV E6/E7 oncogenes, however, at the moment, we cannot rule out the possibility that TACC3 expression is regulated by HPV oncogenes or correlated with the types of HPV.

EGF triggers a cascade of signaling events through interaction with its receptor, EGFR [81], and has been proven to be a potent inducer of EMT in cervical cancer [15]. EGF/EGFR signaling events are associated with accelerated tumor progression of cervical cancer [15,19,82]. In this study, we found that TACC3 was up-regulated upon EGF stimulation, and depletion of TACC3 abolished EGF-mediated EMT process in cervical cells. Moreover, induction of TACC3 by EGF was successfully inhibited by the EGFR inhibitor AG1478, indicating that EGF-mediated TACC3 induction and subsequent EMT are dependent on EGFR activation. Interestingly, we found that in C33A cells, TACC3 expression was much higher than in CaSkI or SiHa cells, despite the absence of EGFR expression. Although our study suggests that EGFR activation may be one of the mechanisms responsible for the regulation of the expression of TACC3, upstream signaling which regulates the expression of TACC3 has not yet been well defined. There has so far been only one published study demonstrating decreased TACC3 protein stability in a Cdh1-dependent manner [83]. TACC3 interacts with an activator of the E3 ubiquitin ligase anaphase-promoting complex/cyclosome (APC/C), Cdh1, and its interaction reduces TACC3 protein stability through Cdh1-mediated ubiquitination and degradation during cell cycle progression. One possibility we consider is that C33A cells may express lower levels of Cdh1 than other cancer cells, thus maintaining high levels of TACC3. Interestingly, unlike SiHa, CaSkI and HeLa cell lines, C33A cells do not harbor HPV genomes but contain mutated p53 [84] and pRb [85]. In addition, various growth factor receptors expressed in C33A are somewhat different from SiHa, CaSkI and HeLa cells [86,87]. Therefore, it is possible that TACC3 expression may be regulated by different signaling pathways depending on cell type.

Supporting Information

Figure S1 The expression of TACC3 in cervical cancer with respect to stage of the disease and histological grading. The expression of TACC3 with different disease stages and tumor grade was presented. *, p<0.05; **, p<0.01; ***, p<0.001 (TIF).

Figure S2 EGF stimulation induces endogenous TACC3 expression. TACC3 was induced by EGF treatment. Cells were incubated with or without 50 ng/ml and then collected at the indicated time points for western blot analysis. β-actin was used as a loading control. (TIF)
Acknowledgments

We thank Dr. M. Denning for helpful discussion and critical reading of the manuscript and A. Peterson for proofreading the manuscript.

Author Contributions

Conceived and designed the experiments: GHH EKB. Performed the experiments: GHH JLK. Analyzed the data: GHH EKB. Contributed reagents/materials/analysis tools: GHH. Wrote the paper: GHH JLK EKB.

References

1. Turley EA, Vieich M, Radisky DC, Bisell MJ (2008) Mechanisms of disease: epithelial-mesenchymal transition—does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 5: 280–290.
2. Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420–1428.
3. Huber MA, Kraut N, Beug H (2005) Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548–558.
4. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139: 871–890.
5. Tanoue B, Rodriguez-Boulan E (2008) The epithelial polarity program: machines involved and their hijacking by cancer. Oncogene 27: 6959–6957.
6. Cheng JC, Auerberg N, Leung PC (2012) EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? PLoS One 7: e34071.
7. Kalluri R (2009) EMT: when epithelial cells decide to become mesenchymal-like. Nat Cell Biol 11: 1417–1419.
8. Kang Y, Massague J (2004) Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277–279.
9. Ha GH, Park JS, Breuer EK (2013) TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett 332: 63–72.
10. Battelle L, Sanchéz E, Franci D, Dominguez D, Monfar M, et al. (2000) The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumors. Nat Cell Biol 2: 84–90.
11. Hajra KM, Chen DY, Fearon ER (2003) The Slug zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 62: 1613–1618.
12. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. (2004) Twist, a BH3 domain-containing protein, promotes epithelial-mesenchymal transitions and tumorigenesis. Cancer Res 64: 4224–4232.
13. Hajra KM, Chen DY, Fearon ER (2003) TACC3 expression is tightly regulated during early differentiation. Gene 315: 197–204.
14. Eger A, Aigner K, Sonderegger S, Dampier B, Oehler S, et al. (2005) DeltaEF1 represses E-cadherin in breast cancer. Cancer Res 62: 1613–1618.
15. Lee MY, Chou CY, Tang MJ, Shen MR (2008) Epithelial-mesenchymal transition: twist in epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 192–201.
16. Still IH, Hamilton M, Vince P, Wolfman A, Cowell JK (1999) Cloning of TACC1, an embryonically expressed, potentially transforming coiled-coil containing gene, from the 8p11 breast cancer amplicon. Oncogene 18: 4032–4038.
17. Lauffert B, Gangsitter O, Still IH (2003) Molecular cloning, genomic structure and interactions of the putative breast tumor suppressor TACC2. Genomics 81: 192–201.
18. Still IH, Vince P, Cowell JK (1999) The third member of the transforming acidic coiled-coil containing gene family, TACC3, maps in 16p16, close to translocation breakpoints in multiple myeloma, and is upregulated in various cancer cell lines. Genomics 58: 165–170.
19. Albre AJ, Wiese C (2008) Xenopus TACC3/maskin is not required for microtubule stability but is required for anchoring microtubules at the centrosome. Mol Biol Cell 19: 3347–3356.
20. Kinosita K, Noetzel TL, Pelletier L, Mechtler K, Drechsel DN, et al. (2005) Aurora A phosphorylation of TACC3/maskin is required for centrosome- dependent microtubule assembly in mitosis. J Cell Biol 170: 1047–1055.
21. Gomez-Baldo L, Schmidt M, Maxwell CA, Boffin N, Gabaldon T, et al. (2010) TACC3-TSC2 maintains nuclear envelope structure and controls cell division. Cell Cycle 9: 1143–1155.
22. Bango S, Raafat A, McCurdy D, Amiandji I, Shu Y, et al. (2010) Transforming acidic coiled-coil protein-3 (Taco-3) acts as a negative regulator of Notch signaling through binding to CD10/Ankyrin repeats. Biochem Biophys Res Commun 400: 606–612.
23. Angrisano T, Lembo F, Pero R, Natale F, Fusco A, et al. (2006) TACC3 mediates the association of MIB2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nuclear Acids Res 34: 364–372.
24. Garriga-Canut M, Orkin SH (2004) Transforming acidic coiled-coil protein 3 (TACC3) controls friend of GATA-1 (FOG-1) subcellular localization and regulates the association between GATA-1 and FOG-1 during hematopoiesis. J Biol Chem 279: 23957–23965.
25. Pickor ZF, Hofeenayr A, Dutsch CD, McKay C, Nakajima H, et al. (2002) The centrosomal protein TACC3 is essential for hematopoietic stem cell function and genetically interfaces with p53-regulated apoptosis. EMBO J 21: 653–664.
26. Duncan CG, Kilalla PJ, Payne CA, Lampson B, Chen WC, et al. (2010) Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget 1: 265–277.
27. Kiemeyer LA, Sulem P, Benenbacher V, Vermeulen SH, Sigurdsson A, et al. (2010) A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet 42: 415–419.
28. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, et al. (2000) Detection of t(14;16)(p11.2;q22) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res 60: 4038–4041.
29. Wang M, Chu H, Yan F, Qin S, Li P, et al. (2011) Chromosome 4p16-3. variant modify bladder cancer risk in a Chinese population. Carcinogenesis 32: 872–875.
30. Guessa JS, Weder NS, Conneally PM, Naylor SL, Anderson MA, et al. (1983) A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306: 234–238.
31. Finelli P, Fabris S, Zagano S, Baldini L, Intini D, et al. (1999) Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by double-color fluorescent in situ hybridization. Blood 94: 724–732.
32. Castro P, Creighton CJ, Ozen M, Berel D, Mims MP, et al. (2009) Genomic profiling of prostate cancer from African American men. Neoplasia 11: 305–317.
33. Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, et al. (2000) Detection of t(14;16)(p11.2;p22) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts. Cancer Res 60: 4038–4041.
72. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, et al. (2006) 
71. Gan Y, Shi C, Inge L, Hibner M, Balducci J, et al. (2010) Differential roles of 
70. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, et al. 
69. Wendt MK, Smith JA, Schiemann WP (2010) Transforming growth factor-beta-
68. Schonrath K, Klein-Szanto AJ, Braunewell KH (2012) The putative tumor 
66. Scotto L, Narayan G, Nandula SV, Arias-Pulido H, Subramaniyam S, et al. 
65. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, et al. 
63. Ulisse S, Baldini E, Toller M, Delcros JG, Gueho A, et al. (2007) Transforming 
62. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using 
60. Yim EK, Tong SY, Ho EM, Bae JH, Um SJ, et al. (2009) Anticancer effects on 
58. Peters DG, Kudla DM, Delouja JA, Chu TJ, Fullard L, et al. (2005) Comparative 
57. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, et al. (2003) Gene 
56. Chakraborty J, Okonta H, Bagalb H, Lee SJ, Fink B, et al. (2008) Retroviral 
55. Kang H, Wilson CS, Harvey RC, Chen IM, Murphy MH, et al. (2012) Gene 
54. Ulisse S, Baldini E, Toller M, Delcros JG, Gueho A, et al. (2007) Transforming 
53. Jung CK, Jung JH, Park GS, Lee A, Kang CS, et al. (2006) Expression of 
52. Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, et al. (2005) 
51. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated 
50. Williams SV, Hurst CD, Knowles MA (2012) Oncogenic FGFR3 gene fusions in 
49. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
48. Lauffart B, Vaughan MM, Eddy R, Chervinsky D, DiCioccio RA, et al. (2005) 
47. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
46. Kodama RE, Kadowaki T, Khan A, Grady H, Liu C, et al. (2007) Epithelial 
45. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
44. Kodama RE, Kadowaki T, Khan A, Grady H, Liu C, et al. (2007) Epithelial 
43. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
42. Kodama RE, Kadowaki T, Khan A, Grady H, Liu C, et al. (2007) Epithelial 
41. Kodama RE, Kadowaki T, Khan A, Grady H, Liu C, et al. (2007) Epithelial 
40. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
39. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
38. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
37. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
36. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
35. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
34. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
33. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
32. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
31. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
30. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
29. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
28. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
27. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
26. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
25. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
24. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
23. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
22. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
21. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
20. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
19. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
18. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
17. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
16. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
15. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
14. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
13. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
12. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
11. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
10. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
9. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
8. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
7. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
6. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
5. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
4. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
3. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
2. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003) 
1. Johns TG, Lowzer RB, Murone C, Walker F, Weinstock J, et al. (2003)